Clinical Trials Browser

Interventional × urelumab × 1 year × Clear all

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02845323 2025-07-15

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell